阿那白滞素治疗COVID-19轻中度肺炎的随机对照试验
CORIMUNO-ANA-1是一项多中心、开放标签、贝叶斯随机对照试验,纳入116例需氧疗但无需通气支持的COVID-19轻中度肺炎患者,比较阿那白滞素联合常规治疗与单独常规治疗。结果显示阿那白滞素未改善第4天WHO-CPS>5比例、第14天无通气生存率或第90天死亡率,严重不良事件两组相似。
核心结论
- 阿那白滞素未改善COVID-19轻中度肺炎患者的预后。
研究设计与样本
- 多中心、开放标签、贝叶斯随机对照试验,嵌套于CORIMUNO-19队列,法国16家大学医院。
- 纳入116例经RT-PCR确诊、需至少3 L/min氧疗但无需通气支持、WHO-CPS评分5分、CRP>25 mg/L的COVID-19轻中度肺炎成人患者。
- 随机1:1分配至阿那白滞素联合常规治疗组(59例)或单独常规治疗组(57例),常规治疗组2例撤回知情同意未分析。
主要发现
- 第90天死亡:阿那白滞素组27%(16例) vs 常规组27%(15例)。
关键数值与推荐
- 阿那白滞素用法:第1-3天200 mg每日两次,第4天100 mg每日两次,第5天100 mg每日一次。
- 纳入标准:WHO-CPS评分5分,CRP>25 mg/L,需至少3 L/min氧疗但无需通气支持。
临床怎么用
- 不推荐对COVID-19轻中度肺炎患者常规使用阿那白滞素改善预后。
- 阿那白滞素在更严重COVID-19患者中的疗效尚需进一步研究。
局限性
- 研究因数据安全监查委员会建议提前终止,样本量116例。
- 开放标签设计,常规治疗由临床医生酌情决定。
- 常规治疗组2例撤回知情同意未纳入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with COVID-19 pneumonia have an excess of inflammation and increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine whether anakinra, a recombinant human IL-1 receptor antagonist, could improve outcomes in patients in hospital with mild-to-moderate COVID-19 pneumonia. METHODS: In this multicentre, open-label, Bayesian randomised clinical trial (CORIMUNO-ANA-1), nested within the CORIMUNO-19 cohort, we recruited patients from 16 University hospitals in France with mild-to-moderate COVID-19 pneumonia, severe acute respiratory syndrome coronavirus 2 infection confirmed by real-time RT-PCR, requiring at least 3 L/min of oxygen by mask or nasal cannula but without ventilation assistance, a score of 5 on the WHO Clinical Progression Scale (WHO-CPS), and a C-reactive protein serum concentration of more than 25 mg/L not requiring admission to the intensive care unit at admission to hospital. Eligible patients were randomly assigned (1:1) using a web-based secure centralised system, stratified by centre and blocked with varying block sizes (randomly of size two or four), to either usual care plus anakinra (200 mg twice a day on days 1-3, 100 mg twice on day 4, 100 mg once on day 5) or usual care alone. Usual care was provided at the discretion of the site clinicians. The two coprimary outcomes were the proportion of patients who had died or needed non-invasive or mechanical ventilation by day 4 (ie, a score of >5 on the WHO-CPS) and survival without need for mechanical or non-invasive ventilation (including high-flow oxygen) at day 14. All analyses were done on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov, NCT04341584, and is now closed to accrual. FINDINGS: Between April 8 and April 26, 2020, we screened 153 patients. The study was stopped early following the recommendation of the data and safety monitoring board, after the recruitment of 116 patients: 59 were assigned to the anakinra group, and 57 were assigned to the usual care group. Two patients in the usual care group withdrew consent and were not analysed. In the analysable population, the median age was 66 years (IQR 59 to 76) and 80 (70%) participants were men. In the anakinra group, 21 (36%) of 59 patients had a WHO-CPS score of more than 5 at day 4 versus 21 (38%) of 55 in the usual care group (median posterior absolute risk difference [ARD] -2·5%, 90% credible interval [CrI] -17·1 to 12·0), with a posterior probability of ARD of less than 0 (ie, anakinra better than usual care) of 61·2%. At day 14, 28 (47%; 95% CI 33 to 59) patients in the anakinra group and 28 (51%; 95% CI 36 to 62) in the usual care group needed ventilation or died, with a posterior probability of any efficacy of anakinra (hazard ratio [HR] being less than 1) of 54·5% (median posterior HR 0·97; 90% CrI 0·62 to 1·52). At day 90, 16 (27%) patients in the anakinra group and 15 (27%) in the usual care group had died. Serious adverse events occurred in 27 (46%) patients in the anakinra group and 21 (38%) in the usual care group (p=0·45). INTERPRETATION: Anakinra did not improve outcomes in patients with mild-to-moderate COVID-19 pneumonia. Further studies are needed to assess the efficacy of anakinra in other selected groups of patients with more severe COVID-19. FUNDING: The Ministry of Health, Programme Hospitalier de Recherche Clinique, Foundation for Medical Research, and AP-HP Foundation.
引用
- Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021. PMID: 33493450. doi:10.1016/S2213-2600(20)30556-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。